Monday, 12 November 2018

Cancer specialists slam decision by health watchdog to NOT recommend a drug for ovarian cancer

Cancer specialists slam decision by health watchdog to NOT recommend a drug for ovarian cancer Cancer specialists have today slammed the 'disappointing' decision by the health watchdog to not recommend an ovarian cancer drug.

The National Institute for Health and Care Excellence (Nice) has said olaparib was not considered to be cost effective.

The 'pioneering' drug is available on the NHS for women with ovarian cancer who have inherited mutations to the BRCA genes.

Studies have shown a larger amount of women could also benefit from the drug. But Nice says it would not expand its use in draft guidelines. The Daily Mail

See also:

No comments:

Post a Comment